Immune cells from cord blood take on Hard-to-Treat cancers
NCT ID NCT06464965
First seen Dec 16, 2025 · Last updated May 03, 2026 · Updated 14 times
Summary
This early-phase study tested a new treatment using specially engineered immune cells (CAR-NK cells) from donated cord blood to target a protein called Claudin18.2 found on some stomach and pancreatic cancer cells. Ten adults with advanced cancer who had no other treatment options received the cells to find the safest dose and check for side effects. The goal was to see if the treatment could shrink tumors or slow the disease, but it is not a cure and ongoing management is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.